Spring direct naar de hoofdnavigatie of de inhoud

Frits Michiels

Patent attorney

‘To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.’
Frits Michiels

Frits Michiels

  • Life Sciences
  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

Continue reading

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Jetze Beeksma

Jetze Beeksma

  • European Patent Attorney
  • Dutch Patent Attorney
  • Associate
Marijke Westra

Marijke Westra

  • European Patent Attorney
  • Dutch Patent Attorney
  • Associate
More experts

News

The Lenoir combustion engine

In 2019, the two-stroke engine is still being used in mopeds and lawnmowers. The technology for this engine came directly from the brain of the French inventor, Lenoir, over 150 years ago.Continue reading

Column – Successful ecosystem for innovation

On a working visit to High Tech Campus Eindhoven, a director of a brand-new campus in the Middle East once complained that his buildings all looked fantastic and the campus was even launched with a video by a Hollywood director. But nothing was happening there. It was only after a few visits to Eindhoven that […]Continue reading

Artificial intelligence offers opportunities for patenting

Innovations based on artificial intelligence and machine learning by computers are becoming increasingly common. V.O. is undoubtedly also interested in these consequences for patents.Continue reading

Events

Managing Trademark Assets Europe 2029

The Bloomsbury Hotel, 16-22 Great Russell St, Bloomsbury, London, UK

As portfolios grow in strength and size, and brand visibility increases, so too do the opportunities for counterfeiters and infringers. But for many, while the risks continue to grow, resources and budgets do not - meaning that companies need to prioritise and build strong trademark management strategies. Continue reading